These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 29129698)

  • 21. Natural Immunity to HIV: A Template for Vaccine Strategies.
    Fourcade L; Poudrier J; Roger M
    Viruses; 2018 Apr; 10(4):. PubMed ID: 29690575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the distribution of IgG and IgA antibodies in serum and various mucosal fluids of HIV type 1-infected subjects.
    Raux M; Finkielsztejn L; Salmon-Céron D; Bouchez H; Excler JL; Dulioust E; Grouin JM; Sicard D; Blondeau C
    AIDS Res Hum Retroviruses; 1999 Oct; 15(15):1365-76. PubMed ID: 10515152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Absence of transmission from HIV-infected individuals with HAART to their heterosexual serodiscordant partners.
    Del Romero J; Río I; Castilla J; Baza B; Paredes V; Vera M; Rodríguez C
    Enferm Infecc Microbiol Clin; 2015 Dec; 33(10):666-72. PubMed ID: 25555636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humans.
    Williams KL; Cortez V; Dingens AS; Gach JS; Rainwater S; Weis JF; Chen X; Spearman P; Forthal DN; Overbaugh J
    EBioMedicine; 2015 Oct; 2(10):1464-77. PubMed ID: 26629541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Maternal Humoral Immune Correlates of Peripartum Transmission of Clade C HIV-1 in the Setting of Peripartum Antiretrovirals.
    Mutucumarana CP; Eudailey J; McGuire EP; Vandergrift N; Tegha G; Chasela C; Ellington S; van der Horst C; Kourtis AP; Permar SR; Fouda GG
    Clin Vaccine Immunol; 2017 Aug; 24(8):. PubMed ID: 28566336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals.
    Mazzoli S; Trabattoni D; Lo Caputo S; Piconi S; Blé C; Meacci F; Ruzzante S; Salvi A; Semplici F; Longhi R; Fusi ML; Tofani N; Biasin M; Villa ML; Mazzotta F; Clerici M
    Nat Med; 1997 Nov; 3(11):1250-7. PubMed ID: 9359700
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive value of anti-cell and anti-human immunodeficiency virus (HIV) humoral responses in HIV-1-exposed seronegative cohorts of European and Asian origin.
    Lopalco L; Barassi C; Paolucci C; Breda D; Brunelli D; Nguyen M; Nouhin J; Luong TT; Truong LX; Clerici M; Calori G; Lazzarin A; Pancino G; Burastero SE
    J Gen Virol; 2005 Feb; 86(Pt 2):339-348. PubMed ID: 15659753
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mucosal and systemic HIV-1-specific immunity in HIV-1-exposed but uninfected heterosexual men.
    Lo Caputo S; Trabattoni D; Vichi F; Piconi S; Lopalco L; Villa ML; Mazzotta F; Clerici M
    AIDS; 2003 Mar; 17(4):531-9. PubMed ID: 12598773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Saliva can mediate HIV-1-specific antibody-dependent cell-mediated cytotoxicity.
    Kim JS; Nag P; Landay AL; Alves M; Cohn MH; Bremer JW; Baum LL
    FEMS Immunol Med Microbiol; 2006 Nov; 48(2):267-73. PubMed ID: 16978244
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IgA immunity in HIV type 1-infected chimpanzees. I. Systemic immunity.
    Black KP; Fultz PN; Girard M; Jackson S
    AIDS Res Hum Retroviruses; 1997 Oct; 13(15):1263-72. PubMed ID: 9339843
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A nonparametric procedure for defining a new humoral immunologic profile in a pilot study on HIV infected patients.
    Brombin C; Diomede L; Tudor D; Drillet AS; Pastori C; Poli E; Riva A; Uberti-Foppa C; Galli M; Di Serio C; Bomsel M; Lopalco L
    PLoS One; 2013; 8(3):e58768. PubMed ID: 23533590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG.
    Tomaras GD; Ferrari G; Shen X; Alam SM; Liao HX; Pollara J; Bonsignori M; Moody MA; Fong Y; Chen X; Poling B; Nicholson CO; Zhang R; Lu X; Parks R; Kaewkungwal J; Nitayaphan S; Pitisuttithum P; Rerks-Ngarm S; Gilbert PB; Kim JH; Michael NL; Montefiori DC; Haynes BF
    Proc Natl Acad Sci U S A; 2013 May; 110(22):9019-24. PubMed ID: 23661056
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Study on factors associated with heterosexual-transmission of human immunodeficiency virus in central China].
    Li L; Li JY; Bao ZY; Liu SY; Zhuang DM; Liu YJ; Feng FM
    Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Nov; 24(11):980-3. PubMed ID: 14687496
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune restoration under HAART in patients chronically infected with HIV-1: diversity of T, B, and NK immune responses.
    Le Guillou-Guillemette H; Renier G; Vielle B; Abgueguen P; Chennebault JM; Lunel F; Payan C
    Viral Immunol; 2006; 19(2):267-76. PubMed ID: 16817769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission.
    Derdeyn CA; Decker JM; Bibollet-Ruche F; Mokili JL; Muldoon M; Denham SA; Heil ML; Kasolo F; Musonda R; Hahn BH; Shaw GM; Korber BT; Allen S; Hunter E
    Science; 2004 Mar; 303(5666):2019-22. PubMed ID: 15044802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-level exposure to HIV induces virus-specific T cell responses and immune activation in exposed HIV-seronegative individuals.
    Restrepo C; Rallón NI; del Romero J; Rodríguez C; Hernando V; López M; Peris A; Lozano S; Sempere-Ortells JM; Soriano V; Benito JM
    J Immunol; 2010 Jul; 185(2):982-9. PubMed ID: 20543099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial.
    Rerks-Ngarm S; Pitisuttithum P; Excler JL; Nitayaphan S; Kaewkungwal J; Premsri N; Kunasol P; Karasavvas N; Schuetz A; Ngauy V; Sinangil F; Dawson P; deCamp AC; Phogat S; Garunathan S; Tartaglia J; DiazGranados C; Ratto-Kim S; Pegu P; Eller M; Karnasuta C; Montefiori DC; Sawant S; Vandergrift N; Wills S; Tomaras GD; Robb ML; Michael NL; Kim JH; Vasan S; O'Connell RJ;
    J Infect Dis; 2017 Apr; 215(8):1255-1263. PubMed ID: 28329190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neutralizing activity and cellular immune responses induced in mice after immunization with apoptotic HIV-1/murine leukemia virus infected cells.
    Hinkula J; Walther-Jallow L; Laurén A; Mäkitalo B; Oberg M; Wahren B; Fenyö EM; Spetz AL
    Vaccine; 2009 Oct; 27(46):6424-31. PubMed ID: 19549607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tracking the Trajectory of Functional Humoral Immune Responses Following Acute HIV Infection.
    Jennewein MF; Mabuka J; Papia CL; Boudreau CM; Dong KL; Ackerman ME; Ndung'u T; Alter G
    Front Immunol; 2020; 11():1744. PubMed ID: 32849622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV-1-specific immunity in persistently seronegative individuals at high risk for HIV infection.
    Beretta A; Furci L; Burastero S; Cosma A; Dinelli ME; Lopalco L; DeSantis C; Tambussi G; Carrow E; Sabbatani S; Clerici M; Lazzarin A; Siccardi AG
    Immunol Lett; 1996 Jun; 51(1-2):39-43. PubMed ID: 8811343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.